CYTOKINETICS DRUG AWARDED ORPHAN DRUG DESIGNATION IN THE US
Cytokinetics initiates second cohort in Phase 2 Trial of CK-2127107
CYTOKINETICS INITIATES PHASE II TRIAL OF POTENTIAL SMA DRUG
In this section
Through this website you are able to link to other websites which are not under the control of Spinal Muscular Atrophy Support UK. Where these links are made as part of an information publication, their inclusion has been subjected to careful review and every effort has been made to ensure they are up to date and appropriate to the topic. This is in line with our commitment to The Information Standard. In all cases, however, we have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
We want this website to offer information that meets the needs of those who use it.Please help us by ticking as many boxes as apply to you: